Concourse Financial Group Securities’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-172
Closed -$7.23K 2449
2022
Q4
$7.06K Hold
172
﹤0.01% 1756
2022
Q3
$7K Buy
172
+1
+0.6% +$43 ﹤0.01% 1583
2022
Q2
$7K Buy
171
+1
+0.6% +$42 ﹤0.01% 1781
2022
Q1
$8K Hold
170
﹤0.01% 1771
2021
Q4
$8K Buy
170
+1
+0.6% +$47 ﹤0.01% 1940
2021
Q3
$8K Hold
169
﹤0.01% 1964
2021
Q2
$9K Buy
169
+1
+0.6% +$50 ﹤0.01% 1912
2021
Q1
$8K Hold
168
﹤0.01% 1844
2020
Q4
$9K Sell
168
-120
-42% -$5.74K ﹤0.01% 1737
2020
Q3
$13K Hold
288
﹤0.01% 1504
2020
Q2
$12K Buy
288
+121
+72% +$5K ﹤0.01% 1446
2020
Q1
$6K Hold
167
﹤0.01% 1621
2019
Q4
$8K Buy
+167
New +$6.62K ﹤0.01% 1513
2019
Q3
Sell
-260
Closed -$9.67K 2176
2019
Q2
$10K Sell
260
-5,410
-95% -$213K ﹤0.01% 1505
2019
Q1
$235K Buy
5,670
+5,504
+3,316% +$224K 0.02% 432
2018
Q4
$6K Buy
+166
New +$7.08K ﹤0.01% 1621

Other funds holding XPH

Concourse Financial Group Securities's XPH Position: Q1 2023 in Review

Concourse Financial Group Securities sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2023, closing a stake of 172 shares — an estimated $7.23K sold.

Concourse Financial Group Securities first reported a position in XPH in Q4 2018 and held it in 16 quarters. The position peaked at $235K in Q1 2019. 61 funds tracked by Wall St. Rank hold XPH as of Q1 2023.

  • Concourse Financial Group Securities reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2023 after selling out during the quarter.
  • Concourse Financial Group Securities sold 172 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2023, an estimated $7.23K.
  • Concourse Financial Group Securities first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2018 and held it in 16 quarters.
  • Concourse Financial Group Securities's State Street SPDR S&P Pharmaceuticals ETF position peaked at $235K in Q1 2019.
  • 61 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2023.

Based on Concourse Financial Group Securities's 13F filing for Q1 2023, filed 15 May 2023.